OakChart

Co-Diagnostics Inc

CODXHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.2778-0.0109 (-3.78%)
2026-11-12 02:35 CET
Market cap
2.64 USD m
Revenue, TTM
0.65 USD m
Net income, TTM
-47.48 USD m
Free cash flow, TTM
-27.19 USD m
EPS diluted, TTM
-18.81
P/E
-
Compare

Price

CODX against its 20, 50 and 200-day averages
2050200earnings
0.005.0010.0059.9M119.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CODXclose 0.2820-day 0.4650-day 0.83200-day 2.090.2852w high

97.9% under the 52-week high of 13.54 on 28 May 2026. 52-week low 0.25 on 6 Nov 2026. Last 15 sessions, 165.3% high to low

Volume 2.05× normal · the line is the 50-bar volume average

Profile

CODX
52-week range, 0% of the way up
0.2513.54

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Employees115
IPOJul 12, 2017
Beta3.22
ATR, 14d0.08
Rel volume2.05
Short float10.62%
Insider own2.61%
Inst own6.64%

Snapshot

6 groups

Valuation

Index-
Market Cap2.64M
Enterprise Value3.49M
Income-47.48M
Sales0.65M
Book/sh1.29
Cash/sh0.07
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees115
IPOJul 12, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S4.06
P/B0.21
P/C3.71
P/FCF-
EV/EBITDA-
EV/Sales5.36
Quick Ratio0.50
Current Ratio0.77
Debt/Eq0.17
LT Debt/Eq0.09
Option/ShortNo / Yes

Earnings

EPS (ttm)-18.81
EPS next Y-0.83
EPS next Q-0.27
EPS this Y91.21%
EPS next Y73.23%
EPS next 5Y80.05%
EPS past 3/5Y-37.47% -
Sales past 3/5Y-76.97% -64.54%
EPS Y/Y TTM34.53%
Sales Y/Y TTM28.89%
EPS Q/Q78.43%
Sales Q/Q94.58%
EarningsNov 10 BMO
EPS/Sales Surpr.19.20% 67.40%

Ownership

Insider Own2.61%
Insider Trans0.00%
Inst Own6.64%
Inst Trans7.63%
ROA-165.04%
ROE-192.78%
ROIC-461.83%
Gross Margin-149.31%
Oper. Margin-4513.05%
Profit Margin-7252.62%
SMA20-39.37%
SMA50-66.67%
SMA200-86.73%
Trades-

Technical

Shs Outstand9.49M
Shs Float9.24M
Short Float10.62%
Short Ratio0.52
Short Interest0.98M
52W High13.54 -97.95%
52W Low0.25 13.39%
Volatility28.50% 18.23%
ATR (14)0.08
RSI (14)24.10
Beta3.22
Rel Volume2.05
Avg Volume1.89M
Volume3,888,316

Performance

Perf Week-23.13%
Perf Month-73.92%
Perf Quarter-81.36%
Perf Half Y-82.64%
Perf YTD-94.51%
Perf Year-97.65%
Perf 3Y-99.19%
Perf 5Y-99.89%
Perf 10Y-
Recom1.00
Target Price4.00
Prev Close0.29
Price0.28
Change %-3.78%

Peers

Mkt cap
TickerCompanyMkt cap
TRIBTrinity Biotech Plc ADR3.72M
AIDX20/20 Biolabs Inc3.00M
BMRABiomerica Inc6.95M
BJDXBluejay Diagnostics Inc3.13M
VNRXVolitionRX Ltd5.69M
INBSIntelligent Bio Solutions Inc6.96M
ADGMAdagio Medical Holdings Inc1.71M
NXLNexalin Technology Inc1.83M
NUWENuwellis Inc2.99M
XAIRBeyond Air Inc4.38M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 94
  • Co-Diagnostics Reports Third Quarter 2026 Financial Results (PR Newswire) -9.50%
  • Co-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and Webcast (PR Newswire) -26.09%
  • Co-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India Launch (PR Newswire)
  • Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast (PR Newswire) -10.49%
  • Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE Test (PR Newswire)
  • Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India (PR Newswire) -14.32%
  • Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum (PR Newswire)
  • Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection (PR Newswire) -6.46%
  • Co-Diagnostics Announces First Full Vector Smart Laboratory Installation for Native American Tribe (PR Newswire)
  • Co-Diagnostics Highlights Vector Smart Momentum Following New Federal Initiative on Vector-Borne Disease (PR Newswire)
  • Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week (PR Newswire)
  • Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation (PR Newswire) +6.80%
  • Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026 (PR Newswire)
  • Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola (PR Newswire) -17.47%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-1.010-1.250-1.2500.280.171
2026Q22026-08-13-1.460--1.4580.17--
2026Q12026-05-14-4.060--4.0560.150.13-
2025Q42026-03-31-16.350-3.600-12.2890.260.132
2025Q32025-11-13-4.800-5.700-4.6610.150.301
2025Q22025-08-14---7.0040.16--
2025Q12025-05-08---7.0520.05--
2024Q32024-11-07---9.5390.64--
2024Q22024-08-08---7.5682.66--
2024Q12024-05-09---9.3610.47--
2023Q32023-11-09---6.1122.46--
2023Q22023-08-10---9.1980.20--
2023Q12023-05-11---5.8560.60--
2022Q32022-11-10---1.3045.09--
2022Q22022-08-11---2.4825.02--
2022Q12022-05-12--10.12422.70--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-37.200-36.600-37.2233.924.14
2025FY-35.250-21.000-37.2000.620.48
2026FY--3.100--0.65
2027FY--0.830--17.31
2028FY--0.280--59.51
2029FY-0.900--136.77
2030FY-2.020--211.57

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-101000.170.170.17
2026Q4S2026-08-141000.170.170.17
2026Q4S2026-04-011000.150.150.15
2026Q4S2026-02-042000.170.150.20
2026Q4S2026-01-222010.170.150.20
2026Q4S2025-12-172010.170.150.20
2026Q4S2025-12-162010.170.150.20
2026Q4S2025-11-252010.170.150.20
2026Q4S2025-11-211010.200.200.20
2026Q4S2025-11-141000.400.400.40
2026Q4S2025-11-111000.400.400.40
2026Q4S2025-11-101000.400.400.40
2026Q4R2026-11-10100-0.27-0.27-0.27
2026Q4R2026-08-14100-0.27-0.27-0.27

Estimate history

EPS, annual-18.9-15.071-11.09245.51236.777-13.569-36.12-37.223-35.255-18.8082
Period201720182019202020212022202320242025TTM
EPS, quarterly-9.539-10.012-7.052-7.004-4.661-12.289-4.056-1.458-1.005
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.0080.040.21574.55397.88634.2180.9910.770.4180.65
Period201720182019202020212022202320242025TTM
Sales, quarterly0.2070.1490.050.1630.1450.060.1460.1660.283
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.4110.4310.5780.9521.1271.0291.0421.1022.0957.289
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.0641.1021.1191.2061.6052.0953.6024.8797.289
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.650.420.770.9934.2297.8974.550.210.04
Cost of Goods Sold Incl. D&A1.631.332.385.426.7611.9116.730.180.06
Gross Profit-0.98-0.91-1.61-4.4227.4585.9857.820.04-0.02
Selling, General and Administrative Excl. Other28.5730.5841.6244.1039.0539.7616.135.936.10
Research and Development18.7619.1420.9822.9617.4414.963.191.371.36
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-29.54-31.49-43.23-48.53-11.5946.2241.69-5.89-6.12
Interest Expense0.000.000.000.000.000.000.000.110.13
Unusual Expense18.8818.880.000.007.490.150.00-0.00
Net Income Before Taxes-47.93-48.51-37.58-38.11-18.8545.6442.57-6.20-6.27
Income Taxes-0.45-1.620.06-2.78-4.618.980.090.000.00
Consolidated Net Income-47.48-46.90-37.64-35.33-14.2436.6642.48-6.20-6.27
Net Income From Continuing Operations-47.48-46.90-37.64-35.33-14.2436.6642.48-6.20-6.27
Net Income-47.48-46.90-37.64-35.33-14.2436.6642.48-6.20-6.27
EPS (Recurring)-5.46-25.32-37.22-36.12-8.5736.8845.51-11.09-15.07
EPS (Basic, Before Extraordinaries)-18.81-35.25-37.22-36.12-13.5738.0947.69-11.09-15.07
EPS (Diluted)-18.81-35.25-37.22-36.12-13.5736.7845.51-11.09-15.07
EBITDA-28.60-30.38-41.85-47.30-10.2846.5541.83-5.83-6.07
Non-Operating Income (Expense)0.501.865.6410.420.23-0.430.88-0.20-0.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.771.784.296.595.964.025.200.590.47
Price To Earnings Ratio----5.477.296.42--
Price To Sales Ratio10.2516.0929.5539.372.322.733.4969.78466.09
Gross Margin-149.31-217.83-208.60-446.2080.2387.8377.5617.04-50.73
Operating Margin-4,513.05-7,529.23-5,613.47-4,894.41-33.8747.2155.93-2,741.61-15,328.65
Net Margin-7,252.62-11,213.62-4,887.88-3,563.67-41.6137.4556.98-2,882.00-15,714.27
Shares Outstanding7.292.101.101.041.031.130.950.580.43
Market Capitalization2.642.6424.7940.7877.91302.01265.5915.5319.26

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.280.170.150.060.150.160.050.15
Cost of Goods Sold Incl. D&A0.530.250.450.410.290.320.300.61
Gross Profit-0.24-0.08-0.30-0.35-0.15-0.16-0.25-0.46
Selling, General and Administrative Excl. Other6.036.128.917.516.877.908.3011.44
Research and Development3.574.155.935.104.484.694.874.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.27-6.20-9.21-7.86-7.01-8.06-8.55-11.91
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.0018.880.000.000.000.00
Net Income Before Taxes-6.31-6.26-9.14-26.22-7.05-7.72-7.52-11.04
Income Taxes0.000.020.00-0.47-1.170.010.01-0.01
Consolidated Net Income-6.31-6.28-9.14-25.75-5.89-7.73-7.53-11.03
Net Income From Continuing Operations-6.31-6.28-9.14-25.75-5.89-7.73-7.53-11.03
Net Income-6.31-6.28-9.14-25.75-5.89-7.73-7.53-11.03
EPS (Recurring)-1.01-1.46-4.06-5.98-4.66-7.00-7.05-10.01
EPS (Basic, Before Extraordinaries)-1.01-1.46-4.06-12.29-4.66-7.00-7.05-10.01
EPS (Diluted)-1.01-1.46-4.06-12.29-4.66-7.00-7.05-10.01
EBITDA-6.05-6.00-8.95-7.60-6.75-7.77-8.27-11.55
Non-Operating Income (Expense)-0.04-0.060.070.53-0.040.341.030.87
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.170.170.230.400.460.691.04
Price To Sales Ratio10.2525.848.1625.3425.6616.2917.4832.19
Gross Margin-85.84-48.76-207.78-587.42-102.00-98.59-500.74-309.97
Operating Margin-2,216.25-3,732.47-6,309.12-13,186.34-4,824.49-4,946.14-17,009.68-7,973.90
Net Margin-2,229.35-3,782.43-6,262.27-43,170.00-4,049.27-4,745.02-14,983.53-7,387.37
Shares Outstanding7.294.883.602.101.601.211.121.10
Market Capitalization2.640.383.9010.6016.5610.1410.3924.79

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments11.8829.7558.5581.2689.8647.310.890.953.53
Short Term Receivables0.230.130.335.4020.9112.140.130.010.00
Inventories0.991.071.665.312.008.000.200.020.01
Other Current Assets0.581.341.600.762.340.920.360.070.91
Total Current Assets13.6932.2962.1492.73115.1268.361.581.054.45
Net Property, Plant & Equipment3.484.886.002.911.930.950.200.160.17
Total Investments and Advances0.350.290.770.671.001.930.430.350.04
Long-Term Note Receivable---0.000.07----
Intangible Assets7.2226.1026.4026.7741.900.000.000.000.00
Deferred Tax Assets2.377.198.335.140.56----
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets27.1270.76103.65128.23160.5971.242.221.554.66
Short Term Debt Incl. Current Port. of LT Debt0.660.920.840.300.000.000.001.910.00
Accounts Payable1.883.291.480.950.610.600.010.150.04
Income Tax Payable---0.002.21----
Other Current Liabilities1.003.113.432.629.783.910.320.290.59
Total Current Liabilities3.547.325.753.8712.604.510.332.350.63
Long Term Debt0.571.242.150.050.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities2.377.198.337.567.79----
Other Liabilities0.001.141.412.225.730.030.150.260.18
Total Liabilities6.4916.8817.6313.7126.124.540.482.610.81
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity20.6353.8886.01114.52134.4866.701.74-1.063.85
Total Shareholders Equity20.6353.8886.01114.52134.4866.701.74-1.063.85
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity20.6353.8886.01114.52134.4866.701.74-1.063.85
Total Liabilities & Stockholders Equity27.1270.76103.65128.23160.5971.242.221.554.66
Book Value Per Share9.8548.9082.55111.28119.2970.063.01-2.469.38
Tangible Book Value Per Share6.4025.2157.2185.2782.1270.063.01-2.469.38
Full-Time Employees11513215514510137232017
Price to Book Ratio0.210.460.410.582.253.988.94-18.196.25
Return on Assets-95.40-43.16-30.48-9.8631.63115.66-328.81-201.81-233.60
Return on Equity-125.15-53.81-35.24-11.4436.45124.14-1,826.40-449.31-1,626.11
Return on Invested Capital-221.18-68.30-40.08-12.4327.2663.69-356.63--180.73
Quick Ratio3.594.2710.5222.578.9813.384.230.447.07
Current Ratio3.874.4110.8123.949.1415.164.830.457.09

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-47.48-46.90-37.64-35.33-14.2436.6642.48-6.20-6.27
Depreciation0.951.111.381.231.310.340.140.070.05
Other Funds (Non Cash)19.8719.824.358.8017.936.052.911.421.37
Funds from Operations-26.66-25.97-31.91-27.720.2043.9844.98-4.71-4.85
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.23-3.172.755.646.37-2.90-16.82-0.820.77
Income Taxes Payable-0.49-0.710.05-0.52-2.202.64---
Cash from Operating Activities-26.88-29.14-29.16-22.086.5741.0828.17-5.53-4.08
Capital Expenditures-0.31-0.70-0.75-1.37-1.43-0.67-0.77-0.11-0.04
Net Assets From Acquisitions0.000.000.000.000.001.200.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-0.3526.9717.8216.75-56.743.57-5.05-0.32-0.34
Purchase of Investments-0.25-6.69-40.95-110.50-68.000.00-10.02-0.32-0.34
Sale Or Maturity of Investments-0.0933.6758.77127.2511.263.574.970.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.6526.2717.0715.39-58.174.10-5.82-0.44-0.38
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock16.8111.810.10-1.36-14.030.4519.745.900.03
Repurchase of Common Pref Stock0.000.000.00-1.36-14.210.000.000.000.00
Sale of Common Pref Stock16.8111.810.100.000.180.4519.745.900.03
Proceedsfrom Stock Options11.6211.800.100.000.000.0018.015.900.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.001.85
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities16.8111.810.10-1.36-14.030.4519.745.901.88
Net Change in Cash-10.738.95-11.98-8.06-65.6345.6342.08-0.06-2.58
Free Cash Flow-27.19-29.84-29.90-23.455.1440.4127.39-5.64-4.12
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Price to Free Cash Flow----15.436.619.51--
Deferred Taxes & Investment Tax Credit-0.000.00-2.42-4.810.93-0.550.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments0.713.658.2311.8811.4413.36
Short Term Receivables0.050.050.080.230.980.21
Inventories0.670.840.850.991.091.08
Other Current Assets0.500.650.620.580.540.65
Total Current Assets1.945.199.7813.6914.0515.31
Net Property, Plant & Equipment3.303.744.163.483.924.34
Total Investments and Advances0.340.440.340.350.660.72
Intangible Assets7.227.227.227.2226.1026.10
Deferred Tax Assets---2.37--
Other Assets0.000.000.000.000.000.00
Total Assets12.7916.5921.5027.1244.7446.47
Short Term Debt Incl. Current Port. of LT Debt0.710.780.860.660.740.82
Accounts Payable0.941.082.021.881.461.64
Other Current Liabilities0.861.001.411.001.491.25
Total Current Liabilities2.512.864.283.543.693.71
Long Term Debt0.851.011.170.570.730.88
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---2.37--
Other Liabilities0.000.000.000.000.490.74
Total Liabilities3.373.885.466.494.915.33
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity9.4312.7116.0420.6339.8341.14
Total Shareholders Equity9.4312.7116.0420.6339.8341.14
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity9.4312.7116.0420.6339.8341.14
Total Liabilities & Stockholders Equity12.7916.5921.5027.1244.7446.47
Book Value Per Share1.292.614.459.8524.8234.11
Tangible Book Value Per Share0.301.132.456.408.5512.47
Full-Time Employees---115--
Price to Book Ratio0.210.020.190.510.420.25
Return on Assets-165.04-149.25-126.56-95.40-54.95-56.60
Return on Equity-192.78-174.77-151.66-125.15-62.12-63.40
Return on Invested Capital-61.35-45.78-53.09-121.43-14.52-18.40
Quick Ratio0.501.522.093.593.513.83
Current Ratio0.771.812.283.873.814.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-6.31-6.28-9.14-25.75-5.89-7.73
Depreciation0.220.200.260.270.270.29
Other Funds (Non Cash)0.290.260.1319.190.500.31
Funds from Operations-5.79-5.82-8.75-6.29-5.12-7.13
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.11-1.330.910.09-0.78-1.16
Income Taxes Payable0.000.000.00-0.49-0.250.01
Cash from Operating Activities-5.68-7.15-7.85-6.20-5.90-8.29
Capital Expenditures-0.02-0.02-0.14-0.13-0.08-0.40
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.00-0.150.00-0.202.2517.47
Purchase of Investments0.00-0.150.00-0.10-0.00-0.14
Sale Or Maturity of Investments0.000.000.00-0.092.2517.62
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.17-0.14-0.332.1717.07
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.762.744.336.974.060.43
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.762.744.336.974.060.43
Proceedsfrom Stock Options-2.412.744.336.964.060.43
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.762.744.336.974.060.43
Net Change in Cash-2.93-4.58-3.650.440.339.21
Free Cash Flow-5.70-7.17-7.99-6.33-5.98-8.69

Revenue breakdown

Grant2024: 3.15M 2025: 204.28K
Product2024: 770.05K 2025: 418.21K
Non-US2024: 391.84K 2025: 40.94K
United States2024: 3.52M 2025: 581.55K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.62%1.0M9.2M360.63K
2026-10-159.05%0.7M7.3M355.64K
2026-09-305.79%0.4M7.2M425.29K
2026-09-154.39%0.3M7.0M426.35K
2026-08-313.10%0.2M6.9M609.23K
2026-08-145.98%0.4M6.1M5.59M
2026-07-315.27%0.3M6.6M5.75M
2026-07-156.86%0.3M5.0M5.79M
2026-06-303.60%0.1M3.5M5.57M
2026-06-153.43%0.1M3.5M6.45M
2026-05-2910.01%0.3M3.5M6.42M
2026-05-155.68%0.2M3.4M1.39M
2026-04-302.88%0.1M3.3M1.19M
2026-04-151.39%0.0M3.3M1.19M
2026-03-315.13%0.2M3.3M1.20M
2026-03-132.97%0.1M1.9M140.03K
2026-02-27-0.0M-64.91K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-04S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-26DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-26SEC
2026-10-16PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-16SEC
2026-10-158-KCurrent report2026-10-14SEC
2026-10-158-K/A2026-10-09SEC
2026-10-138-KCurrent report2026-10-09SEC
2026-10-058-KCurrent report2026-09-30SEC
2026-09-258-KCurrent report2026-09-03SEC
2026-09-21PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-21SEC
2026-09-168-KCurrent report2026-09-16SEC
2026-09-168-KCurrent report2026-09-16SEC
2026-09-158-KCurrent report2026-08-25SEC
2026-09-143Initial statement of beneficial ownership of securities2026-09-02SEC
2026-09-048-KCurrent report2026-09-02SEC
2026-09-04DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-048-KCurrent report2026-09-03SEC
2026-09-01EFFECTEffectiveness filing by commission orderSEC
2026-08-24S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-14SCHEDULE 13GSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-10SCHEDULE 13G/ASEC
2026-07-318-KCurrent report2026-07-30SEC
2026-07-278-KCurrent report2026-07-27SEC
2026-07-27424B5SEC
2026-07-21DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-21SEC
2026-07-10PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-09SEC
2026-06-03SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC6.40%
JANE STREET GROUP, LLC2.42%
VANGUARD CAPITAL MANAGEMENT LLC1.58%
MILLENNIUM MANAGEMENT LLC0.87%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.85%
GEODE CAPITAL MANAGEMENT, LLC0.67%
VANGUARD FIDUCIARY TRUST CO0.54%
Private Advisory Group LLC0.53%
Virtu Financial LLC0.48%
STATE STREET CORP0.40%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.58%
Fidelity Extended Market Index Fund0.46%
Fidelity Series Total Market Index Fund0.09%
Fidelity Total Market Index Fund0.06%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. CODX. Cached 15 minutes.

Some panels did not load: ratings, insider.